A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumo
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
| Condition(s) | Advanced Solid Tumour |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour. |
| Who can participate | Inclusion Criteria: 1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent. 2. Age ≥ 18 years at the time of signing the informed consent. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. 4. The expected survival time is at least 12 weeks. 5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion. 6. Patients with histologically confirmed unresectable locally advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. 7. There is adequate organ and bone marrow function,Conforms to laboratory test results. 8. Males with fertility and females of child |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Nanjing Leads Biolabs Co.,Ltd |
| Locations | Beijing, Beijing Municipality, China; Beijing, Beijing Municipality, China; Shijiazhuang, Hebei, China; Jinan, Shandong, China; Qingdao, Shandong, China; Taiyuan, Shanxi, China (+1 more sites) |
| Start date | 2026-04-13 |
| NCT ID | NCT07390383 |
| Official listing | https://clinicaltrials.gov/study/NCT07390383 |